| LDR | | 03728cmm u2200517 i 4500 |
| 001 | | 000000322669 |
| 003 | | OCoLC |
| 005 | | 20230613115018 |
| 006 | | m d |
| 007 | | cr cnu---unuuu |
| 008 | | 211003s2022 nyua ob 001 0 eng |
| 010 | |
▼a 2021038557 |
| 019 | |
▼a 1273701378 |
| 020 | |
▼a 9780197626313
▼q electronic book |
| 020 | |
▼a 0197626319
▼q electronic book |
| 020 | |
▼a 0197626300
▼q electronic publication |
| 020 | |
▼a 9780197626306
▼q (electronic bk.) |
| 020 | |
▼z 9780195084009
▼q hardcover |
| 035 | |
▼a 3163596
▼b (N$T) |
| 035 | |
▼a (OCoLC)1274229441
▼z (OCoLC)1273701378 |
| 040 | |
▼a DLC
▼b eng
▼e rda
▼c DLC
▼d OCLCF
▼d OCLCO
▼d UKOUP
▼d YDX
▼d EBLCP
▼d OCLCO
▼d N$T
▼d 248032 |
| 042 | |
▼a pcc |
| 049 | |
▼a MAIN |
| 050 | 04 |
▼a HD9999.B442
▼b D73 2022 |
| 082 | 00 |
▼a 338.4/76606
▼2 23/eng/20211004 |
| 100 | 1 |
▼a Drakeman, Donald L.,
▼e author. |
| 245 | 10 |
▼a From breakthrough to blockbuster :
▼b the business of biotechnology /
▼c Donald L. Drakeman, Lisa N. Drakeman, Nektarios Oraiopoulos.
▼h [electronic resource] |
| 264 | 1 |
▼a [New York, NY] :
▼b Oxford University Press,
▼c [2022] |
| 300 | |
▼a 1 online resource (1 volume) :
▼b illustrations |
| 336 | |
▼a text
▼b txt
▼2 rdacontent |
| 337 | |
▼a computer
▼b c
▼2 rdamedia |
| 338 | |
▼a online resource
▼b cr
▼2 rdacarrier |
| 504 | |
▼a Includes bibliographical references and index. |
| 520 | |
▼a "Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. How could a large collection of small companies, most with fewer than 50 employees, compete in one of the world's most breathtakingly expensive and highly regulated industries? This book shows how biotech companies have met the challenge by creating nearly 40% more of the most important treatments for unmet medical needs. Moreover, they have done so with much lower overall costs. The book focuses on both the companies themselves and the broader biotech ecosystem that supports them. Its portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies shows how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. Looking to the future, it concludes that biomedical research will continue to be most effective in the hands of a large group of small companies as long as national healthcare policies allow the rest of the ecosystem to continue to thrive"--
▼c Provided by publisher. |
| 588 | |
▼a Description based on publisher webpage ; title from digital cover (viewed on January 31, 2022). |
| 590 | |
▼a Added to collection customer.56279.3 |
| 650 | 0 |
▼a Biotechnology industries. |
| 650 | 6 |
▼a Bio-industries. |
| 650 | 7 |
▼a Biotechnology industries.
▼2 fast
▼0 (OCoLC)fst00832791 |
| 655 | 4 |
▼a Electronic books. |
| 700 | 1 |
▼a Drakeman, Lisa Natale,
▼e author. |
| 700 | 1 |
▼a Oraiopoulos, Nektarios,
▼e author. |
| 776 | 08 |
▼i Print version:
▼a Drakeman, Donald L.
▼t From breakthrough to blockbuster
▼d New York, NY : Oxford University Press, 2022
▼z 9780195084009
▼w (DLC) 2021038556 |
| 856 | 40 |
▼3 EBSCOhost
▼u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=3163596 |
| 938 | |
▼a EBSCOhost
▼b EBSC
▼n 3163596 |
| 990 | |
▼a 관리자 |
| 994 | |
▼a 92
▼b N$T |